节点文献

凌丹康复方配合DC-CIK治疗白血病临床观察

Effect of Lingdankang Composite Combined Dendritic Cell-Cytokine Induced Killer Cells in Treating Leukemia

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 刘清池吴维海李刚荣胡晓东冯新旺梁春耕武大勇张玉娜庞宇慧王荣孝李建英马传宝张慧敏牛景月

【Author】 LIU Qing-chi,WU Wei-hai,LI Gang-rong,et al Department of Hematology,Ping’an Hospital,Shijiazhuang (050021)

【机构】 河北省石家庄平安医院

【摘要】 目的观察中药凌丹康复方配合树突状细胞联合细胞因子诱导的杀伤细胞(DC-CIK)治疗白血病的临床效果和安全性。方法选择血液学缓解但未达到分子生物学缓解的白血病患者或残留白血病检测阳性患者20例,其中缓解期急性白血病19例,慢性粒细胞白血病1例。用血细胞分离机采集患者的外周血单个核细胞,分别培养DC和CIK,然后再混合培养获得DC-CIK。将DC-CIK经静脉回输给患者,每15~20天回输1次,共输注4~6次。同时服用扶正祛邪中药凌丹康复方。结果凌丹康复方配合DC-CIK治疗20例缓解期白血病患者,达分子生物学缓解,标志基因转阴4例,其中1例为AML1/ETO,1例CBFβ/MYH11,1例IgH基因重排,1例bcr/abl;微小残留白血病转为阴性者3例。治疗后3年完全缓解(CR)为75%,中位CR期25个月(10~37个月)。DC-CIK输注后除5例出现一过性发热,畏寒,无其他严重不良反应。结论中药凌丹康复方配合DC-CIK细胞治疗血液学缓解后白血病,具有明显清除微小残留白血病细胞的作用,是血液学缓解后白血病患者合适的选择,静脉输注安全,有较好的临床应用前景。

【Abstract】 Objective To evaluate the effect and safety of Chinese herbal medicine Lingdankang Composite(LDK) combined dendritic cell-cytokine induced killer cells(DC-CIK) in treating leukemia.Methods Subjects were selected from leukemia patients who achieved hematological complete remission(HCR) but not achieved molecular biological remission(MBR),or with minimal residual leukemia(MRL) positive.Twenty patients,19 of acute leukemia and 1 of chronic myelocytic leukemia,were enrolled.DC and CIK from patient’s peripheral blood monocyte were separated respectively by blood cell separator,then DC-CIK was obtained through respective culture followed with mixed cultivation of them,and was infused back to the patient self via intravenous injection.The back infusion of DC-CIK was performed once every 15-20 days for 4-6 times in total.Meantime,LDK was administered orally every day.Results In the 20 patients treated,4 case of HCR achieved MBR,the negatively reversed marker gene was AML1/ETO in 1 case,CBFβ/MYH11 in 1,bcr/abl in 1,and the other 1 was IgH gene rearrangement;3 patients with positive MRL were reversed to negative.The 3-year CR rate was 75% with a medium CR period of 25 months(10-37 months).Except transient fever and chill in 5 cases,no other remarkable adverse reaction happened during or after DC-CIK infusion.Conclusion The combined treatment of LDK and autologous DC-CIK in treating patients with HCR shows an obvious effect of clearing MRL,it is the appropriate choice for curing leukemia of HCR,and is safety for intravenous infusion,so it has potential clinical prospect.

  • 【文献出处】 中国中西医结合杂志 ,Chinese Journal of Integrated Traditional and Western Medicine , 编辑部邮箱 ,2009年04期
  • 【分类号】R733.7
  • 【被引频次】29
  • 【下载频次】297
节点文献中: 

本文链接的文献网络图示:

本文的引文网络